DEF 14A: Qualigen Seeks Shareholder Approval for $41M Private Placement

Qualigen Therapeutics, Inc. is convening a Special Meeting on November 12, 2025, to seek stockholder approval for a $41 million private placement, a new equity incentive plan, and related share issuances.

Summary

• A Special Meeting of Stockholders is scheduled for November 12, 2025, at 10:00 AM local time, to be held in a virtual-only format.
• Stockholders will vote on four proposals, all of which the Board of Directors unanimously recommends voting FOR.
• Proposal 1 seeks approval for a private placement (the "Offering") of 337,432 shares of common stock and 39,943 shares of Series B Convertible Preferred Stock, totaling $41,000,000, pursuant to a Subscription Agreement dated September 19, 2025.
• Proposal 2 requests approval for the issuance of common stock upon conversion of the Series B Convertible Preferred Stock in excess of the 19.99% share exchange cap, as required by Nasdaq Rule 5635(d).
• Proposal 3 proposes the approval of the 2025 Equity Incentive Plan, which initially allocates 20% of outstanding common stock and includes an annual evergreen increase of 10% of outstanding shares until 2046.
• Proposal 4 is for the approval of adjournments or postponements of the Special Meeting to solicit additional proxies or establish a quorum.
• The company intends to use up to $6,800,000 of the net cash proceeds from the Offering to pay existing debt and fund current business operations, with the balance allocated to establishing cryptocurrency treasury operations.
• The record date for stockholders entitled to notice of and to vote at the Special Meeting was fixed as the close of business on September 22, 2025.

Sentiment

Score: 6

Explanation: The filing outlines necessary procedural steps for a significant capital raise and an equity incentive plan. While the capital raise is positive for funding, the associated dilution and the potential for ongoing expenses if approvals are not met introduce some caution. The strategic move into cryptocurrency treasury operations is notable but carries inherent market volatility.

Positives

• Secured $41,000,000 in cash through a private placement to fund operations and new strategic initiatives.
• A portion of the capital raise, up to $6,800,000, will be used to pay existing debt and support current business operations.
• The establishment of a 2025 Equity Incentive Plan aims to attract, motivate, and retain highly qualified talent, aligning employee interests with stockholder success.
• The balance of the cash proceeds from the offering will be used for the establishment of cryptocurrency treasury operations, indicating a new strategic direction.

Negatives

• The issuance of new common stock and Series B Convertible Preferred Stock will have a dilutive effect on existing stockholders' voting power and economic rights.
• The dilution may result in a decline in the price of common stock or increased price volatility.
• Failure to obtain stockholder approval for the proposals would lead to significant legal expenses and divert management's attention due to the requirement of holding additional special meetings every 90 days.
• The inability to issue Conversion Shares if Proposal 1 is not approved could impact the terms of the private placement.

Risks

• Dilution of existing stockholders' voting power and economic rights due to the issuance of 337,432 common shares and 39,943 Series B Convertible Preferred Stock.
• Potential decline in the market price of common stock or increased price volatility as a result of the new share issuances.
• Risk of incurring significant legal expenses and diverting management's attention if stockholders do not approve the proposals, requiring the company to convene additional special meetings every 90 days.
• Inability to issue Conversion Shares to Series B Convertible Preferred Stock holders if Proposal 1 is not approved.
• Prohibition from issuing additional common stock upon conversion of Series B Convertible Preferred Stock if such issuance exceeds 19.99% of outstanding shares and Proposal 2 is not approved.
• Loss of an important compensation tool to attract, motivate, and retain talent if the 2025 Equity Incentive Plan is not approved.

Future Outlook

The company plans to utilize the $41,000,000 private placement proceeds, allocating up to $6,800,000 for existing debt and business operations, with the remainder dedicated to establishing cryptocurrency treasury operations. The proposed 2025 Equity Incentive Plan is intended to attract and retain key talent. Failure to secure stockholder approval for the proposals would necessitate repeated special meetings every 90 days, incurring significant legal expenses and diverting management attention.

Management Comments

• The Board recommends that you vote FOR Proposals 1, 2, 3, and 4.
• We strongly believe that approval by the stockholders of the Plan will enable us to achieve our goals in attracting and retaining our most valuable asset: our employees.

Industry Context

This filing reflects a common practice for publicly traded companies to seek shareholder approval for significant capital raises and equity compensation plans to ensure compliance with exchange listing rules and corporate governance best practices. The allocation of a substantial portion of the capital raise towards establishing cryptocurrency treasury operations indicates a strategic pivot or expansion into digital asset management, a trend observed in a growing number of companies seeking to diversify their treasury strategies.

Management Changes

Corporate Governance

Related Party Transactions

• Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) participated as a Lead Investor in the $41,000,000 private placement.

Stakeholder Impact

• Shareholders: Face dilution of voting power and economic rights due to the issuance of new common and convertible preferred stock. Have the opportunity to vote on significant corporate actions, including a capital raise and an equity incentive plan.
• Employees/Directors: Stand to benefit from the proposed 2025 Equity Incentive Plan, which aims to attract, motivate, and retain talent through equity awards.
• Creditors: Will see a portion of the $41,000,000 capital raise (up to $6,800,000) used for existing debt repayment.
• New Investors (Subscribers): Will acquire common stock and Series B Convertible Preferred Stock, gaining an equity stake in the company.

Next Steps

• Stockholders are urged to submit proxies or voting instructions for the Special Meeting by November 11, 2025.
• The Special Meeting of Stockholders will be held virtually on November 12, 2025, to vote on the four proposals.
• The company will file a Current Report on Form 8-K with the SEC within four business days after the Special Meeting to disclose voting results.
• If stockholder approval for the private placement or issuance proposals is not obtained, the company is obligated to hold additional stockholder meetings every 90 days until approval is secured.
• The company is required to file a registration statement for the resale of common stock and conversion shares within 45 days of the Offering's closing (September 29, 2025) and use best efforts to have it declared effective 45 days thereafter.

Key Dates

Keywords

Qualigen Therapeutics, QLGN, Proxy Statement, Special Meeting, Private Placement, Equity Incentive Plan, Stockholder Approval, Nasdaq Rules, Dilution, Convertible Preferred Stock, Cryptocurrency Treasury, Capital Raise, Corporate Governance